This clinical trial is focused on studying a type of cancer known as HER2-positive gastric cancer and gastro-esophageal junction adenocarcinoma. These are cancers that occur in the stomach and the area where the stomach meets the esophagus. The study is investigating the effectiveness of a treatment called trastuzumab deruxtecan, also known by its code name DS-8201a. This treatment is being compared to a combination of two other medications, ramucirumab and paclitaxel. The purpose of the study is to see if trastuzumab deruxtecan can help patients live longer compared to the other treatment option.

Participants in the study will receive their assigned treatment through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will follow participants over a period of time to monitor their health and the effects of the treatment. The main goal is to compare the overall survival of patients receiving trastuzumab deruxtecan with those receiving ramucirumab and paclitaxel. Other aspects being studied include how long patients live without the cancer getting worse, how well the cancer responds to the treatment, and any side effects that may occur.

This study is open-label, meaning both the participants and the researchers know which treatment is being given. It is designed to include patients who have already been treated with a regimen containing trastuzumab and have experienced progression of their cancer. The study aims to provide valuable information on the potential benefits and safety of trastuzumab deruxtecan for patients with HER2-positive gastric cancer and gastro-esophageal junction adenocarcinoma.